Do CJC-1295 and Ipamorelin work the same way?

No. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) and works on the GHRH receptor. Ipamorelin is a growth hormone secretagogue that works on the ghrelin receptor. They stimulate growth hormone release through two different receptor pathways, which is why researchers often study them together rather than as substitutes for one another.

Why are CJC-1295 and Ipamorelin commonly sold as a blend?

Because they act on separate receptors, vendors and researchers frequently combine them in one vial rather than as a substitute relationship. The reconstitution and syringe-unit math is identical to any single-peptide vial — the calculator treats the blend's total labeled mass as the vial size.

Is CJC-1295 the same in every vial?

No. CJC-1295 is sold in two distinct forms: with DAC (Drug Affinity Complex), which extends its activity, and without DAC (sometimes labeled Mod GRF 1-29), which clears faster and is dosed more frequently in research protocols. The label should specify which form is in the vial — the calculator's reconstitution math is the same for both, but the research dosing frequency referenced in the literature differs.

Can one calculator handle both CJC-1295 and Ipamorelin?

Yes. The reconstitution formula — concentration equals mass divided by water volume, and units equal volume in mL times 100 on a U-100 syringe — does not change based on which peptide, or which blend, is in the vial.

CJC-1295 vs Ipamorelin: Mechanism and Dosing Compared

By PeptCalc Research — Medically reviewed by David Mansour, MD — Last reviewed July 13, 2026

CJC-1295 and Ipamorelin turn up together constantly in research discussions, usually as a single blended vial rather than as two competing options. They are not interchangeable — each acts on a different receptor pathway — which is exactly why they're often studied in combination. This reference lines up what's different between the two compounds and what stays the same in the reconstitution math. It is written for research and educational purposes only and is not medical advice.

What separates CJC-1295 and Ipamorelin

The difference is mechanism, not potency. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) and acts on the GHRH receptor, prompting the pituitary to release growth hormone. Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor, a separate pathway that also triggers growth hormone release. Because the two compounds work through different receptors, their effects are commonly described as additive rather than redundant — which is the stated rationale for pairing them in a single research protocol rather than choosing one over the other.

CJC-1295 also comes in two distinct forms that are easy to conflate on a vendor label. CJC-1295 with DAC (Drug Affinity Complex) is modified to extend how long it remains active. CJC-1295 without DAC — sometimes labeled Mod GRF 1-29 — clears much faster and is dosed more frequently in research protocols as a result. Ipamorelin does not have a DAC variant; it is a single, short-acting compound. Confirm which CJC-1295 form is on the label before assuming a dosing frequency from an unrelated protocol.

Regulatory and research status

Neither CJC-1295 nor Ipamorelin has an FDA-approved pharmaceutical formulation for human use. Both remain research compounds studied in preclinical and limited early human research rather than approved therapeutics. Neither is discussed here as something to take — this article covers the underlying chemistry and reconstitution arithmetic, not a use recommendation.

Vial formats and typical concentrations

Both peptides reach researchers in one of two formats:

Format	Description
Pre-blended vial	CJC-1295 and Ipamorelin combined by the supplier, commonly at a 1:1 ratio by weight (e.g., 5 mg/5 mg or 2 mg/2 mg). One reconstitution and one draw covers both.
Separate vials	Each peptide reconstituted on its own, with the two draws combined in the syringe or injected separately. This lets the ratio between the two be adjusted independently.

A common reference setup for a 10 mg total blend vial (5 mg CJC-1295 / 5 mg Ipamorelin) uses 2 mL of bacteriostatic water, giving 5 mg/mL total concentration — 2.5 mg/mL of each peptide. That reference point exists because it lands common research doses on clean syringe marks, not because the arithmetic requires it. The peptide calculator recalculates concentration and units for any vial size and water volume you enter.

Worked example: same formula, different receptor targets

The formula is unchanged regardless of which compound, or blend, is in the vial: concentration equals mass divided by water volume, and syringe units equal that volume in mL multiplied by 100 on a U-100 insulin syringe.

CJC-1295 (single vial). A 2 mg vial with 2 mL of bacteriostatic water is 1 mg/mL. A 0.1 mg dose is 0.1 ÷ 1 = 0.1 mL, or 0.1 × 100 = 10 units.

Ipamorelin (single vial). A 5 mg vial with 2 mL of water is 2.5 mg/mL. A 0.3 mg dose is 0.3 ÷ 2.5 = 0.12 mL, or 0.12 × 100 = 12 units.

CJC-1295/Ipamorelin blend. A 10 mg total vial (5 mg/5 mg) with 2 mL of water is 5 mg/mL. A 1 mg dose of the blend is 1 ÷ 5 = 0.2 mL, or 0.2 × 100 = 20 units — half of that draw is CJC-1295 and half is Ipamorelin by weight.

Why one calculator covers both

Here's how we see it: the step where a research dose actually goes wrong isn't the injection, it's the reconstitution math. A U-100 insulin syringe measures a fixed 100 units per mL, so the mg-per-unit depends entirely on how much water went into the vial — and that's true whether the vial holds CJC-1295 alone, Ipamorelin alone, or a blend of both. Mix up the ratio and every draw after is off by the same wrong factor, regardless of which compound is involved. That's why a single reconstitution calculator built on the mass-divided-by-volume formula handles all three vial types without modification. For the full mixing walkthrough, see how to reconstitute peptides.

Where the comparison breaks down

The reconstitution math is identical; the compounds are not. CJC-1295 and Ipamorelin act on different receptors, so a research protocol built around one doesn't automatically transfer to the other — a dose or frequency referenced for Ipamorelin says nothing about the appropriate frequency for CJC-1295 with DAC, whose extended activity is the entire reason its dosing interval differs. Treating the two as interchangeable because they're often sold together is the most common misunderstanding in how this pairing gets discussed.

Common mistakes

Reading a blend ratio as a total. A "5 mg/5 mg" vial contains 10 mg total, not 5 mg. Check whether the label states per-peptide mass or total mass before entering it into the calculator.
Assuming CJC-1295 with DAC and without DAC share a dosing frequency. They don't — the DAC modification is specifically what extends the compound's activity, and protocols built around one form don't transfer to the other.
Confusing mg and mcg. CJC-1295 and Ipamorelin doses are described in milligrams or micrograms depending on the supplier. 1 mg equals 1,000 mcg, and reading one for the other produces a 1,000x error.
Shaking the vial. Swirl gently instead — shaking can degrade the peptide.
Treating the blend ratio as fixed. 1:1 by weight is common, but not universal. Check the specific vial label rather than assuming.

For the full syringe-math walkthrough on the pre-blended vial, see the CJC-1295/Ipamorelin dosage calculator guide. For general mixing steps, see how to reconstitute peptides. Or enter your own vial size, water volume, and target dose directly into the free peptide calculator to see the exact syringe units for either compound or the blend.